Opinion

Video

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Related Videos
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
November 20th 2024

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Joleen Hubbard, MD, medical oncologist, Allina Health Cancer Institute
October 31st 2024

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

Colorectal Cancer
November 15th 2024

GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Loretta Erhunmwunsee, MD
November 4th 2024

City of Hope’s Loretta Erhunmwunsee, MD, Named Cancer Moonshot Scholar by Biden Cancer Moonshot